Last reviewed · How we verify
Fentanyl D-trans
At a glance
| Generic name | Fentanyl D-trans |
|---|---|
| Also known as | Durogesic D-Trans |
| Sponsor | Janssen Korea, Ltd., Korea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain (PHASE4)
- Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain (PHASE4)
- An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics (PHASE4)
- An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain (PHASE4)
- A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant (PHASE2)
- Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl D-trans CI brief — competitive landscape report
- Fentanyl D-trans updates RSS · CI watch RSS
- Janssen Korea, Ltd., Korea portfolio CI